Connor, Clark & Lunn Investment Management (CC&L)’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,041
| Closed | -$1.03M | – | 1676 |
|
|
2025
Q4 | $1.03M | Sell |
6,041
-87,132
| -94% | -$13.4M | ﹤0.01% | 1120 |
|
|
2025
Q3 | $12.3M | Sell |
93,173
-47,799
| -34% | -$5.73M | 0.04% | 366 |
|
|
2025
Q2 | $15M | Buy |
140,972
+8,557
| +6% | +$930K | 0.05% | 297 |
|
|
2025
Q1 | $16.4M | Buy |
132,415
+20,360
| +18% | +$2.66M | 0.07% | 227 |
|
|
2024
Q4 | $13.8M | Buy |
112,055
+93,422
| +501% | +$11M | 0.06% | 245 |
|
|
2024
Q3 | $2.08M | Sell |
18,633
-5,102
| -21% | -$559K | 0.01% | 659 |
|
|
2024
Q2 | $2.53M | Sell |
23,735
-107,281
| -82% | -$11.8M | 0.01% | 592 |
|
|
2024
Q1 | $15.8M | Sell |
131,016
-52,647
| -29% | -$6.45M | 0.07% | 230 |
|
|
2023
Q4 | $22.6M | Buy |
183,663
+7,247
| +4% | +$904K | 0.11% | 161 |
|
|
2023
Q3 | $22.8M | Sell |
176,416
-62,477
| -26% | -$8.32M | 0.12% | 151 |
|
|
2023
Q2 | $29.6M | Buy |
238,893
+12,851
| +6% | +$1.73M | 0.15% | 114 |
|
|
2023
Q1 | $33.1M | Buy |
226,042
+13,028
| +6% | +$1.93M | 0.18% | 107 |
|
|
2022
Q4 | $33.9M | Buy |
213,014
+89,671
| +73% | +$13.1M | 0.2% | 86 |
|
|
2022
Q3 | $16.4M | Buy |
123,343
+35,849
| +41% | +$5.45M | 0.11% | 145 |
|
|
2022
Q2 | $13.7M | Buy |
87,494
+21,307
| +32% | +$3.28M | 0.08% | 171 |
|
|
2022
Q1 | $10.3M | Sell |
66,187
-10,232
| -13% | -$1.48M | 0.05% | 220 |
|
|
2021
Q4 | $9.74M | Buy |
76,419
+35,552
| +87% | +$4.67M | 0.05% | 245 |
|
|
2021
Q3 | $5.32M | Buy |
+40,867
| New | +$6.17M | 0.03% | 324 |
|
|
2019
Q3 | – | Sell |
-3,525
| Closed | -$503K | – | 1017 |
|
|
2019
Q2 | $503K | Sell |
3,525
-2,400
| -41% | -$323K | ﹤0.01% | 717 |
|
|
2019
Q1 | $847K | Buy |
+5,925
| New | +$773K | 0.01% | 561 |
|
|
2018
Q4 | – | Sell |
-1,575
| Closed | -$265K | – | 994 |
|
|
2018
Q3 | $265K | Buy |
+1,575
| New | +$271K | ﹤0.01% | 802 |
|
|
2016
Q3 | – | Sell |
-15,500
| Closed | -$2.19M | – | 876 |
|
|
2016
Q2 | $2.19M | Buy |
+15,500
| New | +$2.28M | 0.02% | 355 |
|
|
2015
Q1 | – | Sell |
-5,300
| Closed | -$868K | – | 593 |
|
|
2014
Q4 | $868K | Sell |
5,300
-19,900
| -79% | -$3.3M | 0.01% | 324 |
|
|
2014
Q3 | $4.05M | Sell |
25,200
-1,700
| -6% | -$261K | 0.03% | 157 |
|
|
2014
Q2 | $4.21M | Sell |
26,900
-17,400
| -39% | -$2.41M | 0.03% | 174 |
|
|
2014
Q1 | $6.78M | Buy |
44,300
+35,800
| +421% | +$5.39M | 0.05% | 140 |
|
|
2013
Q4 | $1.14M | Buy |
+8,500
| New | +$880K | 0.01% | 342 |
|
Other funds holding JAZZ
EC
Connor, Clark & Lunn Investment Management (CC&L)'s JAZZ Position: Q1 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 6,041 shares — an estimated $1.03M sold.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in JAZZ in Q4 2013 and held it in 27 quarters. The position peaked at $33.9M in Q4 2022. 573 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Connor, Clark & Lunn Investment Management (CC&L) sold 6,041 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.03M.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 27 quarters.
- Connor, Clark & Lunn Investment Management (CC&L)'s Jazz Pharmaceuticals position peaked at $33.9M in Q4 2022.
- 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.